Key result
Omitting radiotherapy linked to ~52% lower cardiac mortality in young Hodgkin lymphoma patients.
Why the study?
Although cardiac disease is a leading cause of non-relapse mortality in classical Hodgkin lymphoma, the risk of cardiac-specific mortality in adolescents and young adults remains unclear.
Can a nomogram based on demographic and clinical factors accurately predict 15- and 25-year cardiac-specific mortality in adolescents and young adults with classical Hodgkin lymphoma?
Cohort (n=10,680)
Yes
Can a nomogram based on demographic and clinical factors accurately predict 15- and 25-year cardiac-specific mortality in adolescents and young adults with classical Hodgkin lymphoma?
Effect estimate: HR 0.48 (95% CI 0.36-0.64)
p-value: p=<0.001
A newly developed nomogram using standard clinical variables can accurately predict long-term cardiac-specific mortality in young survivors of classical Hodgkin lymphoma, aiding in risk stratification and targeted cardiac surveillance.
Supports personalized CSM surveillance in AYA cHL survivors; leaves open nomogram utility pending prospective validation.
As survival for classical Hodgkin lymphoma (cHL) improves, cardiac disease is a leading cause of non-relapse mortality, yet the risk of cardiac-specific mortality (CSM) in adolescents and young adults (AYAs) is unclear. This study developed and validated a nomogram to predict CSM for AYAs with cHL using data from the SEER database, with a training cohort of 7,475 patients for model development and a validation cohort of 3,205 patients for internal validation. A Fine-Gray competing risk model was used, with the cumulative incidence of CSM surpassing that of cHL over time. Analysis identified Black race, male sex, older age, earlier diagnosis year, and radiotherapy as significant risk factors for CSM. The resulting nomogram estimates the 15- and 25-year risks of CSM using age, race, sex, diagnosis year, Ann Arbor stage, and radiotherapy. Validation demonstrated strong discriminatory ability via ROC curves, with calibration plots and decision curve analysis confirming its accuracy and clinical utility. This nomogram is a useful tool for predicting CSM in the AYA population and may aid physicians in managing clinical risk factors.
No takes yet. Share an insight, caveat, or question.
Rui et al. (2026) conducted a cohort in Classical Hodgkin lymphoma (n=10,680). No radiotherapy vs. Radiotherapy was evaluated on Cardiac-specific mortality (CSM) (HR 0.48, 95% CI 0.36-0.64, p=<0.001). A validated nomogram for adolescents and young adults with classical Hodgkin lymphoma identified that omitting radiotherapy reduced the risk of cardiac-specific mortality by 52% (HR 0.48).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: